Antithrombotic agents in patients with COVID-19.

Citation metadata

Date: May 24, 2022
From: CMAJ: Canadian Medical Association Journal(Vol. 194, Issue 20)
Publisher: CMA Impact Inc.
Document Type: Article
Length: 611 words
Lexile Measure: 3010L

Document controls

Main content

Article Preview :

1 Coagulopathy and thrombosis are associated with poor outcomes in patients hospitalized with COVID-19

COVID-19 is associated with hypercoagulability and endothelial injury, which contribute to an increased risk of macro- and microvessel thrombosis, disease progression and death. (1)

2 Antithrombotic agents are not recommended for thromboprophylaxis in outpatients with mild COVID-19

In a randomized controlled trial terminated early owing to lower than expected event rates, neither acetylsalicylic acid (ASA) nor apixaban (at prophylactic or therapeutic doses) reduced rates of major adverse cardiovascular or pulmonary events, compared with placebo, in outpatients with mild COVID-19. (2,3)

3 Therapeutic-dose heparin improves survival without organ support in noncritically ill hospitalized patients

Therapeutic-dose low-molecular-weight or unfractionated heparin is recommended for noncritically ill patients in hospital with COVID-19 who are not at high risk of bleeding. (3) In a large trial, therapeutic-dose heparin, compared with usual-care thromboprophylaxis, increased the probability of survival to discharge without organ support (80% v. 76%, number...

Source Citation

Source Citation   

Gale Document Number: GALE|A704355518